Popliteal nerve block including liposomal bupivacaine + Adductor canal nerve block including liposomal bupivacaine + Continuous popliteal nerve block with normal saline + Popliteal nerve block with exclusively unencapsulated bupivacaine + Adductor canal nerve block with exclusively unencapsulated bupivacaine + Continuous popliteal nerve block with unencapsulated bupivacaine
ApprovedRecruitingDevelopment Stage
Moderate-to-severely Painful Ankle Surgery
Moderate-to-severely Painful Ankle Surgery
Jun 23, 2025 → Jun 22, 2027
About Popliteal nerve block including liposomal bupivacaine + Adductor canal nerve block including liposomal bupivacaine + Continuous popliteal nerve block with normal saline + Popliteal nerve block with exclusively unencapsulated bupivacaine + Adductor canal nerve block with exclusively unencapsulated bupivacaine + Continuous popliteal nerve block with unencapsulated bupivacaine
Popliteal nerve block including liposomal bupivacaine + Adductor canal nerve block including liposomal bupivacaine + Continuous popliteal nerve block with normal saline + Popliteal nerve block with exclusively unencapsulated bupivacaine + Adductor canal nerve block with exclusively unencapsulated bupivacaine + Continuous popliteal nerve block with unencapsulated bupivacaine is a approved stage product being developed by Pacira Biosciences for Moderate-to-severely Painful Ankle Surgery. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06995352. Target conditions include Moderate-to-severely Painful Ankle Surgery.
Hype Score Breakdown
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06995352 | Approved | Recruiting |